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Abstract
Recently Granich et al. at theWorld Health Organization (WHO) concluded, using mathematical modeling, that HIV epidemics
could be eliminated within a decade. They assumed all individuals would be tested annually and every infected individual
(regardless of stage of infection) would be put on treatment. Based on this modeling study the WHO is considering using
universal testing and treatment as an HIV elimination strategy. Here we examine the study by Granich et al. and assess its
validity. We present new analyses of their model by varying assumptions and parameter values. We find that under certain
very optimistic assumptions HIV elimination would be (theoretically) possible, but it would take at least 70 years. To obtain
this result we assumed ∼65% of symptomatic and ∼20% of asymptomatic individuals would be treated per year; ARVs would
reduce infectivity of treated individuals a hundred fold, and only 5% of symptomatic individuals would give up treatment per
year. Even under optimistic assumptions we find elimination to be unlikely. For example, we show if ∼65% of symptomatic
individuals are treated per year and treated individuals are completely noninfectious, HIV will remain endemic with a prevalence
of 34% and an incidence of 2% per year. We conclude that the model developed by Granich et al., when used with realistic
parameter values, does not show HIV elimination is possible. However our modeling results show treatment could act as an
effective prevention tool and significantly reduce transmission, even if only symptomatic individuals receive ARVs. Treatment
should first, and foremost, be used for therapeutic purposes. Hence, we recommend when resources are limited - targeting
those in need of treatment. Such a strategy would be ethical, feasible and epidemiologically sound. We advise that models
used as health policy tools should be carefully evaluated and their results interpreted with caution.
I simply wish that, in a matter which so closely concerns the
wellbeing of the human race, no decision shall be made without
all the knowledge which a little analysis and calculation can
provide
Daniel Bernoulli 1760.
1 Introduction
Recently Granich and colleagues at the World Health Orga-
nization (WHO) have used mathematical modeling to assess
the potential impact of antiretrovirals (ARVs) on controlling
HIV epidemics [1]. On the basis of their modeling they con-
cluded that universal testing and treatment with antiretro-
virals (ARVs) could - within a decade - lead to HIV elim-
ination. This finding is now being considered by the WHO
as the basis for making global health policy decisions. How-
ever we propose, before the WHO assume the results from
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the Granich et al. study are correct, the modeling method-
ology be carefully examined to determine its validity. Here,
we conduct such an examination. We also present new re-
sults and compare these with those obtained by Granich et
al.We conclude by discussing the implications of our results
for using ARVs to eliminate HIV.
The Granich et al. study builds on many previous model-
ing studies of HIV and treatment. It was first shown, nearly
a decade ago, in a modeling study by Blower et al. that
widespread use of ARVs could be expected to substantially
reduce HIV incidence rates (as well as death rates) [2]. To
make their predictions Blower et al. assumed that highly ac-
tive ARV regimens, by suppressing viral loads, would reduce
the infectiousness of treated individuals and consequently
decrease transmission [2]. Notably, they also showed that
if risky behavior increased by only ∼10% this could over-
come the effectiveness of ARVs on reducing transmission and
result in incidence increasing [2]. Blower and Farmer were
the first to suggest, in the modeling literature, that ARVs
should be considered as an HIV prevention tool (abeit as
an unconventional tool) because of their effect on reduc-
ing transmission [3]. Since then, many others (e.g., Lima
et al.) have used modeling to show that widespread use of
ARVs could substantially reduce HIV transmission and ar-
gued that ARVs should be considered as prevention tools [4].
The idea that ARVs could potentially be used to eliminate
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HIV epidemics was first proposed by Velasco-Hernandez and
colleagues in 2003 [5]. They conducted a modeling study to
address the question: Could widespread use of combination
antiretroviral therapy eliminate HIV epidemics? They con-
cluded that ARVs can function as very effective HIV pre-
vention tools, even if drug-resistant strains emerge and are
transmitted. However they found elimination would only be
likely if widespread usage of ARVs was accompanied by sub-
stantial reductions in risk behavior [5].
2 Basic Reproduction numbers
Mathematical modelers use the concept of the Reproduction
Number (R) to characterize infectious disease dynamics [6].
The Basic Reproduction Number (R0) is defined as the av-
erage number of new infections one infected individual gen-
erates during their lifetime; assuming the entire population
is susceptible and no biomedical and/or behavioral interven-
tions are in place. Given that R0 is greater than one, an epi-
demic can be expected to occur. The Control Reproduction
Number (RC) is similar to the R0 however it is calculated
based on the assumption that biomedical and/or behavioral
interventions are available. If interventions can reduce the
value of RC to below one it can be concluded that - theoret-
ically - it is possible to eliminate the disease. Mathematical
expressions that specify the R0 and the RC can be derived
from epidemiological models that reflect disease transmis-
sion dynamics. Specific values of R0 and RC can then be
calculated by using estimates of the models parameters.
Based on their modeling, Granich and colleagues concluded
that the value of RC for HIV epidemics could be reduced to
below one (i.e., HIV could - theoretically - be eliminated) if
almost all individuals were tested annually and every HIV-
infected individual (regardless of their stage of infection) was
immediately put on treatment [1]. To reach this conclusion
they also assumed that: only 10% of individuals would give
up treatment per year, and ARVs (by reducing viral load)
would be able to reduce infectivity to 1% of the pretreat-
ment value [1]. Modeling results are always dependent on
the structure of the model and the parameter values that
are chosen. Therefore both the model structure and the pa-
rameter values used in the Granich et al. study need to be
carefully evaluated to assess the validity of the results.
We derived an analytical expression for the RC of a three
stage version of the Granich et al. model (see Supplemen-
tary Information (SI) for technical details); the three stages
correspond to primary infection, asymptomatic with a CD4
count above 350 cells/microL and symptomatic with a CD4
count below 350 cells/microL. We then used the expression
of RC to assess the sensitivity of the results obtained by
Granich et al. to a range of parameter values. Specifically,
we determined what treatment rates and treatment-induced
reduction in infectivity would be necessary to (theoretically)
achieve HIV elimination (i.e., to reduce RC below one).
3 Structure of the Granich et al. model
Simple models can yield important insights into transmis-
sion dynamics; however overly simplistic models can pro-
duce misleading results. Findings should always be assessed
Fig. 1. Flow diagram for the HIV treatment model
constructed by Granich et al. Individuals enter the
sexually active population at a rate pi and leave the
sexually active population at a per capita rate µ . The
S class represents susceptible uninfected individuals,
Ij represent individualswho areHIV infected and un-
treated, while the Aj class represents individuals un-
dergoing antiretroviral therapy. Individuals in class
Ij are treated at a per capita rate τj and subsequently
give up treatment at a per capita rate φj . The pa-
rameters λTj and λ
U
j represent the transmission rates
respectively for treated and untreated individuals in
the jth class and N is the size of the sexually active
population. Treated and untreated HIV infected in-
dividuals in the jth stage of infection progress to the
next stage of infection at respective rates σj and ρj .
Note that in this model there are four stages of infec-
tion; infectivity, treatment rates and dropout rates
are assumed to be identical across all four stages of
infection.
in terms of the assumptions that have been made to con-
struct the model. The structure of the Granich et al. model
is shown in terms of a flow-diagram in Figure 1. The model
is deterministic and specifies the transmission dynamics of
an HIV epidemic in a location where ARVs are widely avail-
able. It was constructed using the following assumptions:
• Individuals can only become infected with HIV through
sexual transmission; vertical transmission is not included.
• The probability/risk of male-to-female transmission is
equal to female-to-male transmission.
• After infection an individual progresses through four
stages before dying of AIDS.
• Viral load (and hence infectivity) is the same in each of
the four stages.
• Individuals can be treated in any of the four stages.
• The model is homogeneous (i.e., every individual in the
model is assumed to be at the same risk for acquiring
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HIV regardless of their gender, age and/or level of sexual
activity).
• The earlier an individual receives treatment the longer
they will survive. The “survival benefit” begins immedi-
ately after infection and individuals who go on treatment
immediately after infection receives the greatest survival
benefits. For example (using the parameter values chosen
by Granich et al.) an individual who is put on treatment
immediately after they become infected will gain (on aver-
age) an additional 11 years, but an individual who is put
on treatment after they have been infected for 6 years will
only gain (on average) an additional 5 years.
• Immediately after universal testing and treatment be-
comes available all infected individuals (whether treated
or not) decrease their risk behavior.
• Individuals who become sexually active after treatment is
introduced are less sexually active than individuals who
were sexually active before treatment was introduced.
• It is not possible for treated individuals to either develop
or transmit drug-resistant strains.
The results obtained by Granich et al. are based on these
assumptions; if these assumptions are not satisfied then the
results do not hold. It is very important to note that the
model developed by Granich et al. cannot show anything
but a beneficial impact of ARVs as the model does not in-
clude the possibility of drug resistance emerging, nor risk
behavior increasing. Previous modeling studies have found
that: (i) even if only 25% of all of the HIV-infected indi-
viduals in Sub-Saharan African receive ARVs the number of
drug-resistant infections, after 5 years, could potentially be
as high as ∼850,000 [2] and (ii) if risk behavior increases by
only 10% the benefits of ARV on reducing transmission are
overcome and incidence remains constant [2].
4 How infectious are treated individuals?
As well as assessing the validity of the results in terms of the
structure of the model, the parameter values that were used
in the modeling should also be closely examined. Granich et
al. assumed ARVs would reduce the infectivity of treated in-
dividuals a hundred fold (i.e., infectivity would be reduced
to 1% of their pretreatment infectivity level) [1]. They use
the term relative infectivity to express reductions in infec-
tivity; where relative infectivity is defined as the ratio of the
infectivity of a treated individual to the infectivity of an un-
treated individual. Consequently a relative infectivity of 0.01
corresponds to a hundred fold reduction in infectivity.
Treatment with ARVs reduces viral load. However, the de-
gree to which treatment-induced reductions in viral load de-
crease infectivity is unknown. Clinical trials designed to as-
sess the effect of ARVs on reducing infectivity, and hence
transmission, are currently underway. However data from
completed studies that have estimated transmission as a
function of viral load can potentially shed some light on the
effect of ARV-induced viral load reduction on decreasing in-
fectivity.
Quinn et al. [7] , Gray et al. [8] and Wawer et al. [9] have
estimated transmission per coital act as a function of vi-
ral load for untreated, heterosexual, discordant couples in
Rakai Uganda. Quinn et al. [7] identified a significant dose-
response relation of increased transmission with increasing
viral load. Specifically, they determined that each log incre-
ment in the viral load was associated with a rate ratio of 2.45
for seroconversion (95 percent confidence interval, 1.85 to
3.26). Smith and Blower [10] formulated a model (based on
the dose-response relationship) that can be used to estimate
the potential effect of ARV-induced viral load reduction on
decreasing per act infectivity. This model, relating viral load
to (per act) infectivity, is shown as Equation 1 and plotted
in Figure 2:
δ(ν) = δb2.45
log10
“
ν
ν
b
”
(1)
In Equation 1 δ and ν respectively represent per act prob-
ability of transmission (i.e., per act infectivity) and plasma
viral load. The parameters δb and νb are baseline infectiv-
ity and viral load which are set equal to 0.0018 and 12,500
copies/mL respectively based on data obtained from the
Quinn et al. study [7].
1 2 3 4 5
0
1
2
3
4
5 x 10
−3
Log10 viral load
In
fe
ct
ivi
ty
 (p
er 
ac
t)
1 2 3
1
2
3
4
x 10−4
Fig. 2. Empirical relationship between viral load and
per coital act infectivity derived by Quinn et al. [7]
(Eq. 1). The dashed blue line represents extrapola-
tion of the curve below the detectable limit of the
study data (i.e., 400 copies/mL).
Granich et al. assume that if ARVs reduce the viral load a
100 fold that infectivity will also be reduced a hundred fold
[1]. However there are no data to support their assumption.
In fact the available empirical data (see Figure 2) show that
a 100 fold decrease in viral load results in only a six fold de-
crease in per act infectivity. Using the statistical relationship
shown in Equation 1, we calculated (see technical details in
the SI) that to reduce the relative infectivity to 0.01 it would
be necessary for treatment to reduce viral load 150,000 fold
(i.e., to essentially eliminate virus within an individual). We
also calculated, that if ARVs cause a four hundred fold re-
duction in viral load the infectivity of treated individuals
will only be reduced 10 fold (i.e., the relative infectivity will
be 0.10) (Figure 2).
It is possible that the relationship between viral load and in-
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fectivity (shown in Equation 1 and Figure 2) may not hold
at low viral loads and/or a viral load threshold may exist at
which transmission risk becomes negligible [11]. In two stud-
ies of heterosexual discordant couples (that included patients
on ARVs) transmission was not observed from individuals
with viral loads less than 400 copies/ml [11]. This could im-
ply a viral load transmission threshold, however (within a
95% confidence interval) the results are also consistent with
one transmission event per 79 person years [11]. Additional
empirical studies have also indicated that a threshold effect
may occur at low viral loads. In six studies of untreated indi-
viduals with viral loads less than 400 copies/mL it was esti-
mated that a mean of only one transmission event occurred
per 625 person years; although (within a 95% confidence in-
terval) these results are also consistent with one transmis-
sion event per 88 person years [11]. Further empirical stud-
ies need to be conducted to determine whether a viral load
transmission threshold exists, as well as to quantify the rela-
tionship between ARV-induced reductions in viral load and
transmission risk.
ARV regimens, when used by fully adherent individuals, may
reduce infectivity below a certain threshold at which indi-
viduals become essentially noninfectious. However the regi-
mens are extremely unlikely to be equally effective in reduc-
ing infectivity in all treated individuals. To eliminate HIV
it is necessary for the ARV regimens to be effective at the
population level, not just at the individual level. Effective-
ness at the population-level will depend on the potency of
the regimens, the level of adherence and the presence of co-
factors (e.g., other sexually transmitted infections). Hence,
even if regimens are extremely potent, a certain proportion
of treated individuals will remain infectious. This is illus-
trated in Figure 3 which shows the relative infectivity in a
population of treated individuals where there is incomplete
adherence. It can be seen that under these conditions, even
if the potency of regimens is such that individuals become
noninfectious, the relative infectivity at the population level
may be as high as 0.3 (Figure 3). Under these conditions,
RC would remain above one and elimination would be im-
possible.
5 Differential treatment (and drop-out) rates
In the modeling conducted by Granich et al. they assumed
that infected individuals, regardless of their stage of in-
fection, would be equally likely to accept treatment. We
examined the consequences of this assumption on the proba-
bility of achieving elimination. To conduct this examination
we made the acceptance rate of treatment a function of
an individuals stage of infection. Specifically, we assumed
that symptomatic individuals (with CD4 counts < 350
cells/microL) would be more likely to accept (and remain
on) treatment than asymptomatic individuals (with CD4
counts > 350 cells/microL).
The results of our analysis are shown in Figure 4. This Figure
shows the conditions that would be necessary to eliminate
HIV; the Y-axis shows the treatment rate for symptomatic
individuals with CD4 counts< 350 cells/microL. The dashed
black curve in Figure 4 delimits the threshold at which RC
equals one; above the curve elimination is (theoretically) pos-
sible and below the curve elimination is not possible. Figure
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Fig. 3. Probability density histogram for the relative
infectivity of symptomatic individuals (CD4 < 350
cells/microL) undergoing treatment assuming realis-
tic levels of adherence and co-factor prevalence. Rel-
ative infectivity is defined as the ratio of the infec-
tivity of a treated individual to the infectivity of an
untreated individual.
Fig. 4. Dependence of the Reproduction Control
number (RC) on treatment rates for symptomatic
(CD4< 350 cells/microL) individuals (Y-axis) and
relative infectivity (X-axis) for anHIV epidemicwith
R0 = 2. Relative infectivity is defined as the ratio
of the infectivity of a treated individual to the in-
fectivity of an untreated individual. Consequently
a relative infectivity of 0.01 corresponds to a hun-
dred fold reduction in infectivity. We assume symp-
tomatic individuals are 5 times as likely to begin
(and 4 times less likely to drop) treatment per year
than asymptomatic individuals. The dropout rate for
symptomatic individuals is 5% per year. The dotted
black curve represents the theoretical threshold for
elimination (RC = 1).
4 is based on two assumptions. Firstly, symptomatic indi-
viduals would be five times more likely than asymptomatic
individuals to be treated. Secondly, asymptomatic individ-
uals would be four times more likely to give up treatment
than symptomatic individuals. It can be seen that elimina-
tion would be (theoretically) possible only if ARV regimens
are able to reduce infectivity 10 fold (i.e., so the relative
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infectivity is less than or equal to 0.10) and 95% of symp-
tomatic individuals with CD4 counts < 350 cells/microL are
treated per year. As we have shown even if regimens are ex-
tremely potent, given realistic levels of adherence, relative
infectivity is very unlikely to be less than 0.10.
6 Estimating the time to eliminate HIV epi-
demics
It is essential to note that even if elimination is shown to
be theoretically possible (i.e., RC can be reduced to below
one), the necessary conditions would have to be maintained
for at least several decades in order to ensure incidence did
not increase.
Figure 5 shows the results of numerical simulations calcu-
lated using the Granich et al. model [1]. The annual HIV
incidence is shown as a function of time from the initiation
of a universal test and treatment program. The curves ter-
minate at the point at which incidence falls below the WHO
elimination threshold of 1 case per thousand per year [1].
The black curve in Figure 5 is generated using the parameter
values of Granich et al. [1] to define their universal test and
treat strategy; to construct this simulation we assumed (as
did they) that infectivity is reduced a 100 fold (i.e., the rela-
tive infectivity is 0.01) and the dropout rate is 1.5% per year.
Under these conditions, it would take ∼20 years to reduce
incidence to the WHO elimination threshold. However, it is
very important to note that after twenty years, when the in-
cidence reaches the elimination threshold, a significant pro-
portion of the population (14%) would still be on treatment.
Consequently, these individuals would have to remain com-
pletely virologically suppressed for at least another decade
in order to keep incidence below the threshold level.
The blue curve in Figure 5 is generated assuming more real-
istic, but still very optimistic, assumptions. To construct this
simulation we assumed ∼65% of symptomatic individuals
(with CD4 counts < 350 cells/microL) and ∼20% of asymp-
tomatic individuals (with CD4 counts > 350 cells/microL)
are treated per year. In addition we assumed the relative
infectivity of treated individuals would be 0.03, and only
5% of symptomatic (and 20% of asymptomatic) individuals
would give up treatment per year. Under these optimistic
assumptions, it can be seen that HIV elimination would be
(theoretically) possible, but it would take over 70 years.
The green curve in Figure 5 is generated assuming ∼65%
of symptomatic individuals (with CD4 counts < 350
cells/microL) would be treated and treated individuals
become completely noninfectious. In this simulation asymp-
tomatic individuals are not treated. Notably, in this case,
even if treatment is completely effective at preventing trans-
mission, HIV will remain endemic in the population with a
prevalence of 34% and an incidence of 2% per year.
It should be noted that none of the simulations presented in
Figure 5, because they are derived using the Granich et al.
model, show the effect of the emergence and transmission
of drug-resistant strains on the incidence of HIV. The emer-
gence of drug resistance will significantly increase the time
it will take to eliminate HIV.
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Fig. 5. : HIV incidence as a function of time for an epi-
demic with basic reproduction numberR0 = 2. Treat-
ment is initiated at time zero. The black and blue
curves terminate when incidence reaches below the
WHO incidence threshold of 1 per thousand per year.
The black curve was simulated using parameters
based on theWHOs universal test and treat strategy,
assuming a relative infectivity of 0.01 and a dropout
rate of 1.5% per year. The blue curve was simulated
assuming: the relative infectivity would be 0.03, and
symptomatic individuals would be 5 times as likely to
begin (and 4 times less likely to drop) treatment per
year than asymptomatic individual. The green curve
was simulated assuming ∼65% of symptomatic indi-
viduals would be treated, asymptomatic individuals
would not be treated, treatment would make individ-
uals completely noninfectious and the dropout rate
would be 5% per year
7 Targetting ARVs
Public health interventions designed for controlling sexually
transmitted diseases (STDs) often aim to target treatment
to individuals in behavioral core groups, because these indi-
viduals disproportionally contribute to transmission. It was
first shown in modeling studies conducted by Hethcote and
Yorke that strategies based on targeting core groups have
the potential to cause a substantial reduction in transmis-
sion of sexually transmitted diseases [12].
We surmise that it may soon be suggested that if ARVs are
going to be used for HIV prevention purposes (and resources
are limited) that ARVs should be targeted to behavioral core
groups. Modeling studies will definitely show targeting ARVs
will be the most effective strategy for reducing transmission
and for using ARVs as a prevention tool. However we argue
strongly that ARVs should not be used in the same manner
as conventional prevention tools and target behavioral core
groups.
A strategy using conventional prevention tools directly ben-
efits uninfected individuals in the core group, but is not
likely to lead to any significant “loss of benefit” to individu-
als who are outside the core group. ARVs should be regarded
as an unconventional prevention tool because they provide
at least two “benefits”: (i) a potential preventive benefit for
uninfected individuals in the community and (ii) most im-
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portantly, a survival benefit for the infected individuals who
receive treatment. If ARVs are regarded as a conventional
prevention tool and behavioral core groups are preferentially
targeted the number of prevented infections will be maxi-
mized. However, such a strategy will ensure that infected in-
dividuals outside the core group will suffer a substantial “loss
of benefit” as they will not receive the therapeutic benefits
of ARVs. Hence targeting ARVs to behavioral core groups
would be the most effective way to reduce transmission, but
would be extremely unethical in terms of treatment equity.
We suggest that targeting the sickest AIDS patients (as has
been done in Haiti [13]) would optimize both therapeutic
and preventive goals. This targeting strategy would be eth-
ical, feasible and epidemiologically sound.
Fig. 6. Dependence of the Reproduction Control
number (RC) on treatment rates for symptomatic
(CD4<350 cells/microL) individuals (Y-axis) and
relative infectivity (X-axis) for anHIV epidemicwith
R0 = 2. Relative infectivity is defined as the ratio of
the infectivity of a treated individual to the infectiv-
ity of an untreated individual. Consequently a rela-
tive infectivity of 0.01 corresponds to a hundred fold
reduction in infectivity. Only symptomatic individu-
als are treated. The dropout rate is 5% per year.
8 Conclusion
ARVs should be made widely available in resource-
constrained countries as they will significantly increase
survival of HIV-infected individuals. ARVs will also reduce
transmission from infected individuals and hence, indirectly,
save lives. Consequently, treatment will function as an
effective prevention strategy.
Treatment should first, and foremost, be used for therapeu-
tic purposes. Since treatment in many resource-constrained
countries is limited it should be provided first to those who
are most in need of treatment. Targeting ARVs to those most
in need is the most ethical strategy. Notably, this strategy
could also significantly reduce transmission (Figure 6). The
treatment rate of symptomatic individuals with CD4 cell
counts less than 350 cells/microL is show on the Y-axis in
Figure 6; in the absence of treatment the R0 equals 2. Fig-
ure 6 shows the higher the treatment rate of symptomatic
individuals and the greater the potency of the ARV regimen
in reducing infectivity the greater the reduction in the RC.
For example, if 80% of symptomatic individuals are treated
and treatment reduces infectivity ten fold the value of the
RC will be 1.3. To put this result in context, this will result
in a reduction in transmission of 35% (see SI for technical
details). It can be seen that achieving a very high treatment
rate (∼95%) would reduce transmission substantially, but
not enough to achieve elimination (Figure 6).
We conclude that the model developed by Granich et al.,
when used with realistic parameter values, does not show
that HIV is (theoretically) possible. We recommend that any
modeling results that are used as a foundation for health
policy decisions should always be carefully examined. Sen-
sitivity analysis should be used to determine the robustness
of results [14]. In addition, assumptions that are made to
construct health policy models should be made transparent
enough to permit policy makers to understand them. Mod-
eling results should always be interpreted with caution. We
recommend that models should never be used as the sole
basis for making health policy decisions; many other, often
more important factors that are not included in the model-
ing framework, need to be considered [15].
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